Increase in [Ca2+]i and subsequent insulin release from beta TC3-cells with the L-type Ca(2+)-channel activator, FPL 64176.
Springborg
J
J
Novo Nordisk A/S, Bagsvaerd, Denmark.
Gromada
J
J
Madsen
P
P
Varming
A R
AR
Fuhlendorff
J
J
D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / Q000494:pharmacology; D000818:Animals; D000952:Antigens, Polyomavirus Transforming / Q000096:biosynthesis / Q000235:genetics; D002118:Calcium / Q000378:metabolism*; D002120:Calcium Channel Agonists / Q000494:pharmacology*; D015220:Calcium Channels / Q000187:drug effects / Q000502:physiology*; D020746:Calcium Channels, L-Type; D004305:Dose-Response Relationship, Drug; D005905:Glyburide / Q000494:pharmacology; D007328:Insulin / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D000078790:Insulin Secretion; D007340:Insulinoma / Q000378:metabolism*; D007700:Kinetics; D051379:Mice; D008822:Mice, Transgenic; D010190:Pancreatic Neoplasms / Q000378:metabolism*; D011401:Promoter Regions, Genetic; D011758:Pyrroles / Q000494:pharmacology*; D013539:Simian virus 40 / Q000235:genetics; D014407:Tumor Cells, Cultured
D000952:Antigens, Polyomavirus Transforming; D002120:Calcium Channel Agonists; D015220:Calcium Channels; D020746:Calcium Channels, L-Type; D007328:Insulin; D011758:Pyrroles; C071658:FPL 64176; D001498:3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester; D005905:Glyburide; D002118:Calcium